Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model

Clinical Rheumatology

Volumn 33, Issue 11, 2014, Pages 1585-1593

  Mao, Xiaoli ^a   Wu, Yunyun ^b   Diao, Huitian ^b   Hao, Jianlei ^b   Tian, Gaofei ^b   Jia, Zhenghu ^b   Li, Zheng ^b   Xiong, Sidong ^c   Wu, Zhenzhou ^b   Wang, Puyue ^b   Zhao, Liqing ^b   Yin, Zhinan ^b  

^a WUHAN UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Activated lymphocyte derived DNA; DC; Interleukin 6; Systemic lupus erythematosus; Treg

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; ANTINUCLEAR ANTIBODY; DNA; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGY; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES, ANTINUCLEAR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-6; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919334570     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2717-9     Document Type: Article

References (30)

1. Tan EM (1989) Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93–151
2. Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, Barrett KJ, Datta SK, Madaio MP (1992) Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 41(6):1690–1700
3. Tebbe B, Orfanos CE (1997) Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 6(2):96–104
4. Qiao B, Wu J, Chu YW, Wang Y, Wang DP, Wu HS, Xiong SD (2005) Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. Rheumatology (Oxford) 44(9):1108–1114
5. Wen ZK, Xu W, Xu L, Cao QH, Wang Y, Chu YW, Xiong SD (2007) DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford) 46(12):1796–1803
6. 4+ T cells. Lupus 21(5):508–516
7. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA (2001) Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14(6):705–714
8. Tanaka T, Kishimoto T (2012) Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 8(9):1227–1236
9. al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S (1993) Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 13(1):58–67
10. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147(1):117–123
11. Aringer M, Smolen JS (2005) Cytokine expression in lupus kidneys. Lupus 14(1):13–18
12. Smolen JS, Steiner G, Aringer M (2005) Anti-cytokine therapy in systemic lupus erythematosus. Lupus 14(3):189–191
13. Qian Y, Conway KL, Lu X, Seitz HM, Matsushima GK, Clarke SH (2006) Autoreactive MZ and B-1 B-cell activation by Faslpr is coincident with an increased frequency of apoptotic lymphocytes and a defect in macrophage clearance. Blood 108(3):974–982
14. Ito T, Schaller M, Hogaboam CM, Standiford TJ, Sandor M, Lukacs NW, Chensue SW, Kunkel SL (2009) TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4. J Clin Invest 119(1):33–46
15. Zhang W, Xu W, Xiong S (2010) Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J Immunol 184(11):6465–6478
16. Zhang W, Xu W, Xiong S (2011) Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol 187(4):1764–1777
17. Zhang W, Wu J, Qiao B, Xu W, Xiong S (2011) Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease. PLoS ONE 6(7):e22659
18. Mevorach D, Zhou JL, Song X, Elkon KB (1998) Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 188(2):387–392
19. Yin Z, Zhang DH, Welte T, Bahtiyar G, Jung S, Liu L, Fu XY, Ray A, Craft J (2000) Dominance of IL-12 over IL-4 in gamma delta T cell differentiation leads to default production of IFN-gamma: failure to down-regulate IL-12 receptor beta 2-chain expression. J Immunol 164(6):3056–3064
20. Wen Z, Xu L, Xu W, Yin Z, Gao X, Xiong S (2013) Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS ONE 8(3):e58161
21. Pisitkun P, Ha HL, Wang H, Claudio E, Tivy CC, Zhou H, Mayadas TN, Illei GG, Siebenlist U (2012) Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 37(6):1104–1115
22. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155(3):1151–1164
23. Kotzin BL (1996) Systemic lupus erythematosus. Cell 85(3):303–306
24. Nath SK, Kilpatrick J, Harley JB (2004) Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol 16(6):794–800
25. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I (2000) Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 18(5):565–570
26. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11(5):613–624
27. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C (2003) IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 24(1):25–29
28. Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, Gonzalez-Amaro R (2006) Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 27(2):110–118
29. Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S (2005) Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 202(10):1333–1339
30. Garrett-Sinha LA, John S, Gaffen SL (2008) IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 20(5):519–525